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Nitric oxide synthesis inhibitor prevents vasodilation by insulin-like 
growth factor I. The effect of insulin-like growth factor I (IGF-I) on 
renal blood flow was measured in the anaesthetized rat using an 
electromagnetic flow probe. Renal vasodilation induced by IGF-I (50 
JLg/kg) was completely inhibited by NG-nitro-l-arginine methyl ester (50 
mg/kg) , an inhibitor of nitric oxide biosynthesis, but only partially 
reduced by indomethacin (10 mg/kg). The involvement of nitric oxide 
synthesis in the renal actions of IGF-I is proposed. 
In the fasted rat, recombinant human insulin-like growth 
factor I (IGF-I) has been shown to increase both renal plasma 
flow and the glomerular filtration rate when administered by 
acute intravenous infusion [1]. A similar increase in both renal 
plasma flow and glomerular filtration rate from the intravenous 
administration of recombinant IGF-I has now been reported in 
two healthy human subjects [2]. The discovery of receptors for 
IGF-I on the vascular endothelium [3] raises the possibility that 
the acute renal response to IGF-I could be mediated by endog-
enous vasodilators synthesized in the endothelium. A role for 
endothelium-derived relaxing factor (EDRF) in mediating renal 
vasodilation has recently been identified from experiments in 
the isolated perfused kidney from the rat [4]. The demonstration 
of nitric oxide as the chemical entity of EDRF [5] and its 
synthesis from I-arginine [6] has allowed arginine analogues to 
be employed as selective inhibitors of nitric oxide biosynthesis 
[7]. In the present study we have investigated the influence of 
one such inhibitor NG-nitro-l-arginine methyl ester (I-NAME) 
on the acute renal vascular response to IGF-I in the anaesthe-
tized rat. 
Methods 
Male Wi star rats (400 to 450 g), allowed free access to water 
but not to food in the 12 hour period prior to experiment, were 
anaesthetized with sodium thiobutabarbitone (In actin) 175 
mg/kg i.p. Each rat received a continuous intravenous infusion 
of sodium chloride 0.45% (100 ILl/min) through a cannula placed 
in the right jugular vein, while systemic blood pressure was 
recorded from the left carotid artery. The body temperature of 
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the rat was maintained at 37°C, and renal blood flow recorded as 
described previously using an electromagnetic flow meter [8]. 
Briefly, following a retro-peritoneal incision, the left renal 
artery was cleared and placed in a non-cannulating electromag-
netic flow probe (2 mm circumference) attached to a flowmeter 
(Carolina). When necessary, small arterial branches leaving the 
right renal artery were tied to ensure a good fit between the 
renal artery and the probe. Zero flow was established by 
occlusion of the renal artery distal to the probe. 
IGF-I was diluted in isotonic saline to 100 ILg/ml and deliv-
ered by short (10 min) continuous i. v. infusion through a syringe 
pump (Microeject, Carnegie, UK). Neither the additional fluid 
volume (40 ILl/min) nor the IGF-I drug vehicle had any effect on 
renal blood flow. L-NAME was dissolved in 0.45% sodium 
chloride and indomethacin was dissolved in 0.5 M sodium 
carbonate, and the pH adjusted to pH 8.5. Both I-NAME and 
indomethacin were each delivered by a lO-minute intravenous 
infusion, 15 minutes prior to the administration of IGF-1. 
All results were expressed as mean ± SEM and compared 
using the Mann-Whitney test on Microtab software. 
Materials were: Recombinant human IGF-I (Kabi-Vitrum, 
Sweden), I-NAME (Serva, FRG), indomethacin (Sigma Chem-
ical Co., St. Louis, Missouri, USA). 
Results 
IGF-I (50 ILg/kg) produced a sustained increase in renal blood 
flow which started to rise at the end of the 10 minute infusion 
period, reaching its maximum about four to six minutes after 
the infusion had finished. At this dose the response was 
sustained and lasted for approximately 30 to 40 minutes. The 
time course of this response is shown in Figure 1. At its 
maximum, IGF-I 50 ILg/kg produced a significant increase in 
total renal blood flow from 8.5 ± 0.4 to 10.6 ± 0.5 ml/min (P < 
0.002, N = 13). This was accompanied by a small but significant 
fall in systemic blood pressure from 108 ± 5 to 101 ± 6 mm Hg 
(P < 0.05) and a significant decrease in renal vascular resistance 
from 13.0 ± 0.6 to 9.7 ± 0.5 mm Hg/ml/min (P < 0.001). 
Dose-response experiments to a short intravenous infusion of 
IGF-I (N = 3) showed a dose-related increase in renal blood 
flow which could first be detected at a dose of 0.25 ILg/kg. 
In a separate series (N = 11), the intravenous administration 
ofl-NAME 50 mg/kg produced a 51.3 ± 4.2% fall in renal blood 
flow (P < 0.001, N = 11), the systemic blood pressure increas-
ing from 97 ± 5 to 153 ± 5 mm Hg (P < 0.001; Table 1). IGF-I 
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Fig. 1. The mean increase in renal blood flow produced by IGF-I (50 
J-Lglkg) administered alone (e. N = /3) or 15 minutes after pretreatment 
with I-NAME 50 mglkg ( •. N = /1) or indomethacin 10 mglkg ( .... N = 
6). 
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Fig. 2. Comparison between the change in renal blood flow (RBF). 
systemic blood pressure (BP) and renal vascular resistance (RVR) 
produced by an intravenous infusion of IGF-I 50 J-Lglkg either alone (N 
= /3) unhatched columns. or following pretreatment with I-NAME 50 
mglkg (N = 11) hatched columns. 
50 JLg/kg was administered intravenously, 15 minutes after the 
addition of I-NAME 50 mg/kg. The effect of I-NAME on the 
renal vasodilation induced by IGF-I is shown in Figure 2, where 
the change in renal vascular resistance has been calculated as a 
percent control of values obtained prior to IGF-I administra-
tion. In the presence of I-NAME, IGF-I 50 JLg/kg produced no 
significant change in renal blood flow (3.3 ± 0.21 to 3.5 ± 0.31 
mllmin), systemic blood pressure (153 ± 5.9 to 151 ± 6.1 mm 
Hg) or renal vascular resistance (48.1 ± 4.6 to 47.2 ± 5.3 mm 
Hg/mllmin). 
In a further series (N = 6), indomethacin (10 mg/kg) had little 
effect on either basal renal blood flow or systemic blood 
pressure (Table 1). The time course of the increase in renal 
blood flow produced by an intravenous infusion of IGF-I 50 
JLg/kg administered 15 minutes after indomethacin 10 mg/kg is 
Table 1. Effect of NG-nitro-I-arginine methyl ester (50 mg/kg, N = 
II) and indomethacin (10 mg/kg, N = 6) on renal vascular resistance 
in the anaesthetized rat 
Renal blood 
flow mllmin 
Systemic blood 
pressure mm Hg 
Renal vascular 
resistance mm 
Hglmllmin 
"P < 0.001 
L-NAME 
50 mglkg 
Control Experimental 
7.1 ± 0.5 3.3 ± 0.2" 
97 ± 6 153 ± 6" 
13.8 ± 1.0 48.1 ± 4.6a 
Indomethacin 
10 mglkg 
Control Experimental 
7.3 ± 0.1 7.4 ± 0.1 
129 ± 2 127 ± 3 
18.0 ± 0.5 16.6 ± 0.5 
shown in Figure 1. IGF-I still produced a significant increase in 
renal blood flow from 7.4 ± 1 to 8.8 ± 0.2 ml/min (P < 0.05) and 
decreased renal vascular resistance from 16.6 ± 0.5 to 13.1 ± 
0.5 mm Hg/mllmin (P < 0.05). Although the mean systemic 
blood pressure was lower at 114 ± 3 mm Hg compared to 127 ± 
3 mm Hg, the difference was not significant at the 5% level. 
However, following indomethacin 10 mg/kg, the maximum 
increase in renal blood flow produced by IGF-I was significantly 
lower (30%) than in the control series (P < 0.05). 
Discussion 
Renal vasodilation induced by IGF-I has previously been 
demonstrated in the rat fasted for 72 hours to reduce the plasma 
levels of IGF-I binding protein [1]. The demonstration of 
increased renal blood flow following the administration of IGF-I 
to two healthy volunteers [2] indicates that the normal levels of 
IGF-I binding proteins do not prevent a renal response to 
exogenous IGF-I from being detected. The results of the 
present rat experiments support this view since prolonged 
fasting was not required to demonstrate renal vasodilation in 
the anaesthetized rat to exogenous IGF-1. A similar total dose 
of IGF-I, 50 JLg/kg, was employed as in previous rat experi-
ments, but in addition to the increase in renal blood flow a 
significant fall in systemic blood pressure was observed. This 
small hypotensive response could be accounted for solely by 
the change in resistance of the renal vascular bed, indicating 
that following intravenous administration, IGF-I may exert a 
selective effect on the kidney. Preliminary dose-response stud-
ies showed that renal vasodilation induced by IGF-I could be 
detected at doses down to 0.25 JLg/kg, representing an addition 
of approximately 10 ng/ml IGF-I to circulating blood. The 
electromagnetic flow probe is probably a more sensitive indi-
cator of acute changes in renal blood flow [9] than the method 
of PAH clearance employed previously [1]. 
Following the discovery of I-arginine as the precursor of 
nitric oxide [6], I-NAME is one of a number of arginine 
analogues including monomethylarginine and nitro-arginine 
now used to inhibit nitric oxide synthesis [7]. Treatment with 
I-NAME completely inhibited the decrease in renal vascular 
resistance produced by IGF-I 50 JLg/kg, indicating the involve-
ment of nitric oxide synthesis in this response. Nitric oxide is 
synthesized in the endothelial lining of blood vessels [5] where 
the presence of receptors for IGF-I has now been demonstrated 
[3]. Unlike indomethacin, however, I-NAME had an important 
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effect on basal renal vascular resistance in this preparation, 
renal blood flow being halved, and renal vascular resistance 
increasing some 3.5-fold together with a 60 mm Hg increase in 
blood pressure. An acute increase in blood pressure per se does 
not prevent the renal vasodilator response to IGF-I, which 
could still be demonstrated following an increase in blood 
pressure produced in the rat by an intravenous infusion of 
noradrenaline (J. Haylor, unpublished observation). Hyperten-
sion is a property common to all arginine analogues which are 
inhibitors of nitric oxide synthesis [7], indicating an important 
contribution of nitric oxide to the maintenance of vascular tone. 
A similar increase in renal vascular resistance to I-NAME has 
recently been demonstrated in a re-circulating model of the 
isolated perfused rat kidney [10]. 
IGF-I induced renal vasodilation has previously been attrib-
uted to an increase in the synthesis of another vasodilator 
produced by the endothelium, prostacyciin, since the response 
was reduced by the cycio-oxygenase inhibitor, indomethacin 
[1]. In the present experiments, however, only 30% of the peak 
response to IGF-I was abolished by indomethacin 10 mg/kg, a 
maximal inhibitory dose on the rat kidney [11]. This suggests 
that following stimulation with IGF-I, there may be a compo-
nent of the response common to both the nitric oxide and 
prostacyciin pathways in the kidney. Indomethacin itself had 
little effect on either renal blood flow or the systemic blood 
pressure, probablY due to the use retro-peritoneal surgery and 
the maintenance of an adequate fluid balance. 
In addition to increasing renal blood flow, IGF-I can increase 
the glomerular filtration rate [1,2], and receptors for IGF-I have 
now been located on the glomerular endothelium [12]. IGF-I 
may also be involved in compensatory renal growth, since in 
the rat the renal tissue levels of IGF-I increase following 
uninephrectomy [13, 14]. The ability of I-NAME to inhibit 
compensatory growth [15] and of sodium nitroprusside to 
stimulate mitogenesis [16] have recently been demonstrated. 
Such observations indicate that a study of the role of nitric 
oxide in other renal properties of IGF-I warrants further inves-
tigation. 
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